Published: 2016-12-28

Efficacy and safety of various drugs used for the treatment of nonneurogenic lower urinary tract symptoms in tertiary care hospital

Shikha Dwivedi, Dilip Chander Dhasmana, Manoj Biswas, Vimal Kumar Dixit, Neeraj Kumar Agrawal


Background: Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) are common in elder men. Previously surgical treatment was mainstay of treatment of BPH. But now number of drugs alone or combined are clinically used for this disorder. Primary aim was to study the prescribing pattern of different drug therapies and their role in treating LUTS/BPH by evaluating their efficacy and safety in tertiary health care centre.

Methods: An observational study including 78 male patients ≥45 years, newly diagnosed with LUTS from April 2014 to May 2015. Patients were followed up every 4 weeks for 3 months after the drug has been prescribed. Efficacy assessment was done on basis of change in IPSS score over 12 weeks. Data was expressed in percentage and Mean ±SD.

Results: Mean age of Patients was 64.94 years. Alpha blockers are mainstay prescribed drug either as monotherapy (48.7%) or with 5 alpha reductase inhibitor-dutasteride (38.4%) and with antimuscarinic –Tolterodene (12.8%). Among alpha blockers Tamsulosin (58.97%) was most commonly prescribed, followed by Silodosin (20.5%) and Alfuzosin (20.5%). All drug treatment results in significant improvement with dizziness being the most common adverse event. A subgroup analysis in symptoms was done comparing alpha blockers. All alpha blockers have near about similar efficacy with no significant difference.

Conclusions: Alpha blockers are main drugs prescribed in management of LUTS/BPH with near about similar efficacy of all alpha blockers.


LUTS, Prescribing pattern, Alpha blockers, Efficacy

Full Text:



Abrams PCC, Khoury S, Roehrborn C, Rosette J. Supplement on Men's Health Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men. Journal of Urology. 2013;189(1):93-101.

Rosette J. Definitions: LUTS, BPH, BPE, BOO, BPO. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in Men. 2011:1.

Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Wein A, Kavoussi LR, Novick A, et al, editors. Campbell-Walsh urology, vol. 2. 9th edition. Philadelphia: Saunders. 2007:2727-65.

Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate. Clin Ther. 2007.

Roehrborn CG. Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). Med Clin N Am. 2011;95:87-100.

Hakimi ZJM, Nazir J, Blak B, Odeyemi IA. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Curr Med Res Opin. 2015;31(1):43-50.

Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64:1081-8.

Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332-5.

A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. J Int Med Res. 2005;33(5):562-73.

Chapple CR, Montorsi F, Tammela TL, Wirth M,

Koldewijn E, Fernández Fernández E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342-52.

Joseph SDH MA, Wei JT, Sarma AV, Dunn RL, Taylor JMG. Risk Factors for Lower Urinary Tract Symptoms in a Population-based Sample of African-American Men. American Journal of epidemiology. 2002;127(10):906-14.

Yu HJ, Lin AT, Yang SS, Tsui KH, Wu HC, Cheng CL. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. 2011;108:1843-8.

Pande SHA, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. IJP. 2014;46(6 601).

American Urological Association Education and Research, authors. Results of the Treatment Outcomes Analyses. 2006. [Accessed November 10, 2009]. pp. 1–142. (Guideline on the Management of Benign Prostatic Hyperplasia (BPH)). clinicalguidelines/main-reports/bph management/chapt_3_appendix.